Today is your last chance to donate during Public Media Giving Days, a time to celebrate what public and independent media gives to you by giving back. If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. In honor of Public Media Giving Days, a generous donor will TRIPLE your donation, which means it’ll go 3x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets tripled! Thank you so much.
-Amy Goodman
Today is your last chance to donate during Public Media Giving Days, a time to celebrate what public and independent media gives to you by giving back. If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. In honor of Public Media Giving Days, a generous donor will TRIPLE your donation, which means it’ll go 3x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets tripled! Thank you so much.
-Amy Goodman
We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.
Please do your part today.
StoryMay 02, 2024
StoryMay 02, 2024
StoryMay 02, 2024
StoryMay 02, 2024
Web ExclusiveMay 01, 2024
Web ExclusiveApr 29, 2024
Web ExclusiveApr 23, 2024
Web ExclusiveApr 23, 2024
Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified “potential safety concern.” President Trump touted a similar drug produced by Regeneron as a “cure” for COVID-19 after he received a dose while hospitalized at Walter Reed Medical Center earlier this month. Both Eli Lilly and Regeneron have applied for emergency use authorizations of their antibody therapies.
Top